Fetal Neural Transplantation in the Treatment of Parkinson's and Huntington

Two diseases, one hope: Fetal nerve transplantation of Parkinson's disease and Huntington's disease Parkinson's disease (PD) and Huntington's disease (HD) are neurodegenerative diseases caused by dysfunction of the nervous system nervous system. These dysfunctions caused by hormonal excess (such as HD) or absence (such as PD) are a direct consequence of worsening neurons in the brain. PD and HD subsequently show two different behavioral patterns caused by two opposite extreme biological abnormalities.

Major neurological disorders - Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis (Lou Gehrig disease) - all involve the loss of nerve cells and nerve cells. Essentially, neurons in the brain, neurons are supported by astrocyte and oligodendrocyte or glial cell function, providing comprehensive support of neurons. Dr. Kurtzberg 's recently reported evidence suggests that glial cells from donor umbilical cord blood stem cells will grow in the brains of her patients undergoing treatment for genetic disorders.

Shelly: My paper project focuses on the development of new treatments for the treatment of neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, Parkinson's disease. All of these diseases have one thing in common. Brain cells gradually accumulate toxic proteins and inhibit the normal molecular mechanism of the cells. As these proteins accumulate, neurons die. There is some evidence that removing toxic proteins contributes to neuronal survival and delay of symptoms (at least in mice). I led the project to develop a modular peptide drug for protein knockout. Once injected into the bloodstream, it passes through the blood brain barrier, grabs its target toxic protein, and drags it into cellular organelle called lysosome, the cell's own waste treatment system. Peptides can be customized for different kinds of toxic proteins by exchanging one of the modules (eg Lego).

Treatment for Parkinson's disease also indicates hope and we face similar obstacles. Clinical trials have been conducted on transplantation of human fetal mesencephalic tissue (tissue derived from the midbrain forming part of the brain stem) into the striatum of Parkinson's disease patients. However, due to the limited availability of such organizations, ESC migration is more attractive. In fact, studies have shown that implantable dopaminergic neurons, Parkinson 's diseased neurons, can be produced from mouse, primate and human embryonic stem cells. However, one of the big differences between mouse and human embryonic stem cells is that it takes time to differentiate human embryonic stem cells (up to 50 days). In addition, the procedure for differentiation of human embryonic stem cells requires the introduction of animal sera for breeding, which may violate certain medical regulations in some countries. However, each study improves differentiation and purification techniques